Piroxicam in Veterinary Oncology: NSAID Evidence and Interaction Safety

piroxicam is covered as nonsteroidal anti-inflammatory drug used extra-label in selected veterinary oncology contexts, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Nonsteroidal anti-inflammatory drug used extra-label in selected veterinary oncology contexts. Piroxicam.

Piroxicam.

Piroxicam inhibits cyclooxygenase activity and prostaglandin production. Anti-inflammatory and analgesic effects are established pharmacologic actions; tumour-related effects observed in some canine carcinomas are context-specific and cannot be generalised to every cancer.

Canine urothelial carcinoma is the best-known oncology setting, including use alone or with chemotherapy in clinical studies. It may also be discussed for palliation or selected protocols. It is not a substitute for diagnosis, staging or the comparison of surgery, radiation and systemic options.

Canine urothelial carcinoma is the best-known oncology setting, including use alone or with chemotherapy in clinical studies. It may also be discussed for palliation or selected protocols. It is not a substitute for diagnosis, staging or the comparison of surgery, radiation and systemic options.

Oral systemic medicine prescribed and monitored by a veterinarian

Prospective and retrospective canine studies report disease-control signals in urothelial carcinoma, but response and toxicity vary by combination. A randomized trial did not establish that one piroxicam-containing chemotherapy combination was superior to the other. The evidence does not justify a universal anticancer claim.

Gastrointestinal ulceration or bleeding, kidney injury, appetite loss, vomiting and diarrhoea are central concerns. Older oncology patients may have dehydration, kidney disease or concurrent medicines that increase risk. Cats require especially cautious species-specific NSAID decisions; this page does not recommend piroxicam for cats.

Piroxicam must not be casually combined with another NSAID or a glucocorticoid. Diuretics, renin-angiotensin system medicines, anticoagulants and nephrotoxic chemotherapy can alter risk. A veterinarian determines any washout period and whether the expected benefit justifies the interaction burden.

Piroxicam is not listed among currently marketed FDA-approved NSAIDs for dogs or cats and is not FDA-approved as a canine or feline cancer drug. US veterinary oncology use is extra-label under AMDUCA conditions.

Extra-label oncology use and product availability vary by jurisdiction. A human product or local veterinary supply must not be presented as an approved animal-cancer indication.

A baseline medication reconciliation, hydration assessment, blood count, kidney and liver profile and urinalysis may be relevant. Follow-up should capture appetite, vomiting, stool colour, drinking, urination, weight, pain/function and objective tumour status. Urgent gastrointestinal or renal signs require veterinary contact. No dose is provided.